Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

✍ Scribed by De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martine (author);Holmes, Eileen (author);Di Cosimo, Serena (author);Swaby, Ramona F. (author);Untch, Michael (author);Jackisch, Christian (author);Lang, Istvan (author);Smith, Ian (author);Boyle, Frances (author);Xu, Binghe (author);Barrios, Carlos H. (author);Perez, Edith A. (author);Azim, Hatem A. (author);Kim, Sung Bae (author);Kuemmel, Sherko (author);Huang, Chiun Sheng (author);Vuylsteke, Peter (author);Hsieh, Ruey Kuen (author);Gorbunova, Vera (author);Eniu, Alexandru (author);Dreosti, Lydia (author);Tavartkiladze, Natalia (author);Gelber, Richard D. (author);Eidtmann, Holger (author);Baselga, José (author)

• Book ID: 125851235
• Publisher: Lancet Publishing Group
• Year: 2014
• Tongue: English
• Weight: 325 KB
• Volume: 15
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(14)70320-1